Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

hEGFRvIII-CD3 (BRiTE)

Phase 1Small molecule

MMustafa Khasraw, MBChB, MD, FRCP, FRACP

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Newly Diagnosed GlioblastomaRecruiting

Newly Diagnosed GlioblastomaPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Newly Diagnosed Glioblastoma

NCT04903795

Clinical

Trials by Indication[1]

Newly Diagnosed Glioblastoma1 trial

A Phase 1 Study of Bispecific T Cell Engager (BRiTE) in Patients With Newly Diagnosed or Recurrent Glioblastoma

Recruiting·MMustafa Khasraw, MBChB, MD, FRCP, FRACP·Phase 1·NCT04903795·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for hEGFRvIII-CD3 (BRiTE). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hEGFRvIII-CD3 (BRiTE) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hEGFRvIII-CD3 (BRiTE). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mustafa Khasraw, MBChB, MD, FRCP, FRACP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMustafa Khasraw, MBChB, MD, FRCP, FRACP

Related News